Enhancement of Transamniotic Stem Cell Therapy for Spina Bifida by Genetic Engineering of Donor Mesenchymal Stem Cells with an Fgf2 Transgene

Genetic engineering of donor mesenchymal stem cells with Fgf2 transgene significantly improves spina bifida defect coverage in transamniotic stem cell therapy, increasing coverage rates from 38.5% to 73.3% in a rodent model. This approach represents a promising enhancement strategy for prenatal treatment of neural tube defects.